Results 41 to 50 of about 577,054 (155)

Optimizing timing of adolescent vaccines: Impact of initiating HPV vaccination before Tdap or meningococcal vaccination on timely completion of the HPV vaccine series

Human Vaccines & Immunotherapeutics, 2023
To explore the impact on timely series completion of initiating the HPV vaccine series prior to other vaccines in the adolescent platform (Tdap or meningococcal vacccines), we created a cohort of children aged 9 in 2015 who were continuously enrolled ...
Sidika Kajtezovic, Jake R. Morgan, Stephen Fiascone, Heather M. Brandt, Rebecca B. Perkins   +4 more
doaj   +1 more source

Updated Recommendations for Use of MenB-FHbp Serogroup B Meningococcal Vaccine — Advisory Committee on Immunization Practices, 2016

MMWR. Morbidity and mortality weekly report, 2017
Two serogroup B meningococcal (MenB) vaccines are currently licensed for use in persons aged 10-25 years in the United States. The two vaccines are MenB-FHbp (Trumenba, Pfizer, Inc.) (1) and MenB-4C (Bexsero, GlaxoSmithKline Biologicals, Inc.) (2).
M. Patton, D. Stephens, Kelly L. Moore, Jessica R Macneil   +3 more
semanticscholar   +1 more source

The cost-effectiveness of alternative vaccination strategies for polyvalent meningococcal vaccines in Burkina Faso: A transmission dynamic modeling study. [PDF]

PLoS Medicine, 2018
BACKGROUND:The introduction of a conjugate vaccine for serogroup A Neisseria meningitidis has dramatically reduced disease in the African meningitis belt.
Reza Yaesoubi, Caroline Trotter, Caroline Colijn, Maziar Yaesoubi, Anaïs Colombini, Stephen Resch, Paul A Kristiansen, F Marc LaForce, Ted Cohen   +8 more
doaj   +1 more source

Molecular characterization of invasive Neisseria meningitidis isolates collected in Lithuania (2009-2019) and estimation of serogroup B meningococcal vaccine 4CMenB and MenB-Fhbp coverage

Frontiers in Cellular and Infection Microbiology, 2023
Neisseria meningitidis causes invasive meningococcal disease (IMD), which is associated with significant mortality and long-term consequences, especially among young children.
Emilija Sereikaitė, Rūta Plepytė, Aurelija Petrutienė, Aurelija Petrutienė, Dovilė Stravinskienė, Indrė Kučinskaitė-Kodzė, Vilmantas Gėgžna, Inga Ivaškevičienė, Inga Ivaškevičienė, Aurelija Žvirblienė, Milda Plečkaitytė   +10 more
doaj   +1 more source

Incidence of Meningococcal Disease Before and After Implementation of Quadrivalent Meningococcal Conjugate Vaccine in the United States.

JAMA pediatrics, 2020
Importance In 2005, the US Advisory Committee on Immunization Practices recommended routine quadrivalent meningococcal conjugate (MenACWY) vaccine for all adolescents aged 11 to 12 years, and in 2010, a booster dose for adolescents aged 16 years ...
Sarah A Mbaeyi, Tracy Pondo, Amy E. Blain, D. Yankey, Caelin C. Potts, A. Cohn, S. Hariri, N. Shang, Jessica R Macneil   +8 more
semanticscholar   +1 more source

Vaccines against Meningococcal Diseases

Microorganisms, 2020
Neisseria meningitidis is the main cause of meningitis and sepsis, potentially life-threatening conditions. Thanks to advancements in vaccine development, vaccines are now available for five out of six meningococcal disease-causing serogroups (A, B, C, W,
Mariagrazia Pizza, Rafik Bekkat-Berkani, Rino Rappuoli   +2 more
doaj   +1 more source

Construction of Opa-positive and Opa-negative strains of Neisseria meningitidis to evaluate a novel meningococcal vaccine. [PDF]

PLoS ONE, 2012
Neisseria meningitidis is a major global pathogen causing invasive disease with a mortality of 5-10%. Most disease in developed countries is caused by serogroup B infection, against which there is no universal vaccine.
Manish Sadarangani, J Claire Hoe, Martin J Callaghan, Claire Jones, Hannah Chan, Katherine Makepeace, Hélène Daniels-Treffandier, Mary E Deadman, Christopher Bayliss, Ian Feavers, Peter van der Ley, Andrew J Pollard   +11 more
doaj   +1 more source

Safety and immunogenicity of co-administration of meningococcal type A and measles–rubella vaccines with typhoid conjugate vaccine in children aged 15–23 months in Burkina Faso

International Journal of Infectious Diseases, 2020
Highlights • This is the first study on the co-administration of typhoid conjugate vaccine (TCV) in West Africa.• Co-administration of TCV with routine vaccines in a typhoid-endemic country was successful.• TCV was safely co-administered at 15 months ...
S. Sirima, A. Ouédraogo, N. Barry, M. Siribie, A. Tiono, I. Nebie’, A. Konaté, G. D. Berges, A. Diarra, Moussa Ouedraogo, I. Soulama, Alimatou Héma, Shrimati Datta, Yuanyuan Liang, Elizabeth T. Rotrosen, J. Tracy, Leslie P. Jamka, K. Neuzil, M. Laurens   +18 more
semanticscholar   +1 more source

Suboptimal uptake of meningococcal vaccines among older adolescents: Barriers, solutions, and future research directions

Human Vaccines & Immunotherapeutics, 2020
Over the past 15 y, several vaccines have been added to the recommended immunization schedule for adolescents in the United States. In addition to annual influenza vaccination, the Advisory Committee on Immunization Practices recommends tetanus ...
Linda M. Niccolai, Caitlin E. Hansen
doaj   +1 more source

Safety and Immunogenicity of Meningococcal Groups A and C Polysaccharide Vaccine in Adults 18–60 years of age

Эпидемиология и вакцинопрофилактика, 2023
Relevance. In the Russian Federation, despite the low incidence rate in 2020–2021, there are subjects where the incidence rate of meningococcal infection (MI) exceeds the national average by 2–9 times.
V. V. Romanenko, B. I. Kuzubov, N. A. Tsukanova, A. A. Kotova   +3 more
doaj   +1 more source